Don't Just Read the News, Understand It.
Published loading...Updated

Viral vector in LGMD2E gene therapy gets new FDA designation

Summary by Muscular Dystrophy News
The FDA granted platform technology designation to the viral vector used in the LGMD2E gene therapy SRP-9003.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Muscular Dystrophy News broke the news in on Tuesday, June 10, 2025.
Sources are mostly out of (0)